The New Drug Reimbursement Game

A Regulator’s Guide to Playing and Winning

Nonfiction, Health & Well Being, Medical, Specialties, Pharmacy, Medical Science, Pharmacology
Cover of the book The New Drug Reimbursement Game by Brita A.K. Pekarsky, Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Brita A.K. Pekarsky ISBN: 9783319089034
Publisher: Springer International Publishing Publication: October 9, 2014
Imprint: Adis Language: English
Author: Brita A.K. Pekarsky
ISBN: 9783319089034
Publisher: Springer International Publishing
Publication: October 9, 2014
Imprint: Adis
Language: English

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation.  It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation.  The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. 

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare.  The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.   

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated.  Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system.  Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price.  PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.  

 

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation.  It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation.  The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. 

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare.  The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.   

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated.  Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system.  Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price.  PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.  

 

More books from Springer International Publishing

Cover of the book Landform Dynamics and Evolution in Romania by Brita A.K. Pekarsky
Cover of the book Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions by Brita A.K. Pekarsky
Cover of the book Digitalization and Public Sector Transformations by Brita A.K. Pekarsky
Cover of the book Artificial Intelligence in Medicine by Brita A.K. Pekarsky
Cover of the book Risks and Security of Internet and Systems by Brita A.K. Pekarsky
Cover of the book Understanding International Students from Asia in American Universities by Brita A.K. Pekarsky
Cover of the book Software Technologies by Brita A.K. Pekarsky
Cover of the book Sonochemical Production of Nanomaterials by Brita A.K. Pekarsky
Cover of the book Examining Text and Authorship in Translation by Brita A.K. Pekarsky
Cover of the book ArcGIS for Environmental and Water Issues by Brita A.K. Pekarsky
Cover of the book Atlas of Head and Neck Robotic Surgery by Brita A.K. Pekarsky
Cover of the book Experiences from Surface Water Quality Monitoring by Brita A.K. Pekarsky
Cover of the book Energy Efficient Embedded Video Processing Systems by Brita A.K. Pekarsky
Cover of the book Approximation by Max-Product Type Operators by Brita A.K. Pekarsky
Cover of the book Abatement Techniques for Reducing Emissions from Livestock Buildings by Brita A.K. Pekarsky
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy